Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by vla-4 inhibition and suppression of monocyte and T cell infiltration into the CNS

NeuroMolecular Medicine

Volumn 16, Issue 2, 2014, Pages 292-307

  Lee, Jun Ho ^a   Halperin Sheinfeld, Meital ^b   Baatar, Dolgar ^a   Mughal, Mohamed R ^a   Tae, Hyun Jin ^a   Kim, Jie Wan ^a   Carter, Arnell ^a   Lustig, Ana ^a   Snir, Omri ^b,c   Lavie, Gad ^c   Okun, Eitan ^b   Mattson, Mark P ^a,d   Sredni, Benjamin ^b   Taub, Dennis D ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Integrin; Macrophages; Multiple sclerosis; Spinal cord; VLA 4

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ARGINASE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; RANTES; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4; AMMONIUM TRICHLORO(DIOXOETHYLENE-O,O'-)TELLURATE; CYTOKINE; ETHYLENE DERIVATIVE; IMMUNOLOGIC FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MONOCYTE; MOTOR PERFORMANCE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; SHAM PROCEDURE; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD BRAIN BARRIER; BRAIN; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SPINAL CORD; SPLEEN; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ETHYLENES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTEGRIN ALPHA4BETA1; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MONOCYTES; MULTIPLE SCLEROSIS; SPINAL CORD; SPLEEN; T-LYMPHOCYTE SUBSETS;

EID: 84901339790     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8277-3     Document Type: Article

References (60)

1. Ahmed, Z., Doward, A. I., Pryce, G., Taylor, D. L., Pocock, J. M., Leonard, J. P., et al. (2002). A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: Inflammation versus degeneration. American Journal of Pathology, 161, 1577-1586.
2. Bar-Or, A., Rieckmann, P., Traboulsee, A., & Yong, V. W. (2011). Targeting progressive neuroaxonal injury: Lessons from multiple sclerosis. CNS Drugs, 25, 783-799.
3. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. The New England Journal of Medicine, 366, 1870-1880.
4. Brodsky, M., Halpert, G., Albeck, M., & Sredni, B. (2010). The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFkappaB signaling pathway and nitric oxide induction in macrophages. Journal of Inflammation (London), 7, 3.
5. Brodsky, M., Yosef, S., Galit, R., Albeck, M., Longo, D. L., Albeck, A., et al. (2007). The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. Journal of Interferon and Cytokine Research, 27, 453-462.
6. Dalton, C. M., Miszkiel, K. A., Barker, G. J., MacManus, D. G., Pepple, T. I., Panzara, M., et al. (2004). Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. Journal of Neurology, 251, 407-413.
7. Dhib-Jalbut, S. (2007). Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology, 68, S13-S21.
8. Floris, S., Ruuls, S. R., Wierinckx, A., van der Pol, S. M., Döpp, E., van der Meide, P. H., et al. (2002). Interferon-beta directly influences monocyte infiltration into the central nervous system. Journal of Neuroimmunology, 127, 69-79.
9. Friedman, M., Bayer, I., Letko, I., Duvdevani, R., Zavaro-Levy, O., Ron, B., et al. (2009). Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: Assessment of its safety and efficacy. British Journal of Dermatology, 160, 403-408.
10. Frohman, E. M., Racke, M. K., & Raine, C. S. (2006). Multiple sclerosis - The plaque and its pathogenesis. New England Journal of Medicine, 354, 942-955.
11. Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., & Ley, K. (2010). Development of monocytes, macrophages, and dendritic cells. Science, 327, 656-661.
12. Geurts, J. J., & Barkhof, F. (2008). Grey matter pathology in multiple sclerosis. Lancet Neurology, 7, 841-851.
13. Gonsette, R. E. (2008). Oxidative stress and excitotoxicity: A therapeutic issue in multiple sclerosis? Multiple Sclerosis, 14, 22-34.
14. Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., et al. (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nature Medicine, 11, 328-334.
15. Haider, L., Fischer, M. T., Frischer, J. M., Bauer, J., Höftberger, R., Botond, G., et al. (2011). Oxidative damage in multiple sclerosis lesions. Brain, 134, 1914-1924.
16. Hendriks, J. J. A., Teunissen, C. E., Vries, H. E. D., & Dijkstra, C. D. (2005). Macrophages and neurodegeneration. Brain Research Reviews, 48, 185-195.
17. Holman, D. W., Klein, R. S., & Ransohoff, R. M. (2011). The blood-brain barrier, chemokines and multiple sclerosis. Biochimica et Biophysica Acta, 1812, 220-230.
18. Huitinga, I., Nv, Rooijen., Groot, C. J. A. D., Uitdehaag, B. M. J., & Dijkstra, C. D. (1990). Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. Journal of Experimental Medicine, 172, 1025-1033.
19. Huo, Y., Hafezi-Moghadam, A., & Ley, K. (2000). Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circulation Research, 87, 153-159.
20. Indenbaum, V., Bin, H., Makarovsky, D., Weil, M., Shulman, L. M., Albeck, M., et al. (2012). In vitro and in vivo activity of AS101 against West Nile virus (WNV). Virus Research, 166, 68-76.
21. Jack, C., Ruffini, F., Bar-Or, A., & Antel, J. P. (2005). Microglia and multiple sclerosis. Journal of Neuroscience Research, 81, 363-373.
22. Jones, J. L., & Coles, A. J. (2010). New treatment strategies in multiple sclerosis. Experimental Neurology, 225, 34-39.
23. Kalechman, Y., Sredni, B., Weinstein, T., Freidkin, I., Tobar, A., Albeck, M., et al. (2003). Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. Journal of the American Society of Nephrology, 14, 620-630.
24. + T cell-mediated immunosuppression, suggesting dual roles in the disease process. Journal of Immunology, 178, 6695-6699.
25. + myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood, 113, 3190-3197.
26. Kivisakk, P., Imitola, J., Rasmussen, S., Elyaman, W., Zhu, B., Ransohoff, R. M., et al. (2009). Localizing central nervous system immune surveillance: Meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Annals of Neurology, 65, 457-469.
27. Lassmann, H. (2010). Axonal and neuronal pathology in multiple sclerosis: What have we learnt from animal models. Experimental Neurology, 225, 2-8.
28. Leussink, V. I., Zettl, U. K., Jander, S., Pepinsky, R. B., Lobb, R. R., Stoll, G., et al. (2002). Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathologica, 103, 131-136.
29. Martinou, J. C., & Youle, R. J. (2011). Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Developmental Cell, 21, 92-101.
30. McCormack, P. L. (2013). Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis. Drugs, 73, 1463-1481.
31. Meuth, S. G., Göbel, K., & Wiendl, H. (2012). Immune therapy of multiple sclerosis - future strategies. Current Pharmaceutical Design, 18, 4489-4497.
32. Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8, 958-969.
33. Niino, M., Bodner, C., Simard, M. L., Alatab, S., Gano, D., Kim, H. J., et al. (2006). Natalizumab effects on immune cell responses in multiple sclerosis. Annals of Neurology, 59, 748-754.
34. Noonan, C. W., Williamson, D. M., Henry, J. P., Indian, R., Lynch, S. G., Neuberger, J. S., et al. (2010). The prevalence of multiple sclerosis in 3 US communities. Preventing Chronic Disease, 7, A12.
35. Okun, E., Arumugam, T. V., Tang, S. C., Gleichmann, M., Albeck, M., Sredni, B., et al. (2007). The organotellurium compound ammonium trichloro(dioxoethylene-0,0′) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. Journal of Neurochemistry, 102, 1232-1241.
36. Okun, E., Mattson, M. P., & Arumugam, T. V. (2010). Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Medicine, 12, 164-178.
37. Prat, A., & Antel, J. (2005). Pathogenesis of multiple sclerosis. Current Opinion in Neurology, 18, 225-230.
38. Prendergast, C. T., & Anderton, S. M. (2009). Immune cell entry to central nervous system-current understanding and prospective therapeutic targets. Endocrine, Metabolic & Immune Disorders: Drug Targets, 9, 315-327.
39. Rezai-Zadeh, K., Gate, D., & Town, T. (2009). CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? Journal of Neuroimmune Pharmacology, 4, 462-475.
40. Shani, A., Tichler, T., Catane, R., Gurwith, M., Rozenszajn, L. A., Gezin, A., et al. (1990). Immunologic effects of AS101 in the treatment of cancer patients. Natural Immunity Cell Growth Regulation, 9, 182-190.
41. Sheremata, W. A., Minagar, A., Alexander, J. S., & Vollmer, T. (2005). The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs, 19, 909-922.
42. Smyser, G. S. (1973). Counterstaining Golgi-Cox impregnations with luxol fast blue as a myelin stain. Stain Technology, 48, 53-57.
43. Sredni, B. (2012). Immunomodulating tellurium compounds as anti-cancer agents. Seminars in Cancer Biology, 22, 60-69.
44. Sredni, B., Albeck, M., Tichler, T., Shani, A., Shapira, J., Bruderman, I., et al. (1995). Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. Journal of Clinical Oncology, 13, 2342-2353.
45. Sredni, B., Caspi, R. R., Klein, A., Kalechman, Y., Danziger, Y., Ben Ya'akov, M., et al. (1987). A new immunomodulating compound (AS-101) with potential therapeutic application. Nature, 330, 173-176.
46. Sredni, B., Gal, R., Cohen, I. J., Dazard, J.-E., Givol, D., Gafter, U., et al. (2004a). Hair growth induction by the Tellurium immunomodulator AS101: Association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB Journal, 18, 400-402.
47. Sredni, B., Geffen-Aricha, R., Duan, W., Albeck, M., Shalit, F., Lander, H. M., et al. (2007). Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB Journal, 21, 1870-1883.
48. Sredni, B., Tichler, T., Shani, A., Catane, R., Kaufman, B., Strassmann, G., et al. (1996). Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. Journal of National Cancer Institute, 88, 1276-1284.
49. Sredni, B., Weil, M., Khomenok, G., Lebenthal, I., Teitz, S., Mardor, Y., et al. (2004b). Ammonium trichloro(dioxoethylene-o, o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Research, 64, 1843-1852.
50. Steinman, L. (2005). Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nature Reviews Drug Discovery, 4, 510-518.
51. Steinman, L. (2009). A molecular trio in relapse and remission in multiple sclerosis. Nature Reviews Immunology, 9, 440-447.
52. Strassmann, G., Kambayashi, T., Jacob, C. O., & Sredni, D. (1997). The immunomodulator AS-101 inhibits IL-10 release and augments TNF alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. Cellular Immunology, 176, 180-185.
53. Susin, S. A., Zamzami, N., & Kroemer, G. (1998). Mitochondria as regulators of apoptosis: Doubt no more. Biochimica et Biophysica Acta, 1366, 151-165.
54. Swanborg, R. H. (1995). Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clinical Immunology and Immunopathology, 77, 4-13.
55. Theien, B. E., Vanderlugt, C. L., Nickerson-Nutter, C., Cornebise, M., Scott, D. M., Perper, S. J., et al. (2003). Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood, 102, 4464-4471.
56. van der Laan, L. J., van der Goes, A., Wauben, M. H., Ruuls, S. R., Döpp, E. A., De Groot, C. J., et al. (2002). Beneficial effect of modified peptide inhibitor of alpha4 integrins on experimental allergic encephalomyelitis in Lewis rats. Journal of Neuroscience Research, 67, 191-199.
57. Wayner, E. A., Garcia-Pardo, A., Humphries, M. J., McDonald, J. A., & Carter, W. G. (1989). Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. The Journal of cell biology, 109, 1321-1330.
58. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature, 356, 63-66.
59. Yusuf-Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J. (2002). Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews, 22, 146-167.
60. + Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. Journal of Immunology, 179, 5228-5237.